Ublituximab Market Report 2026

Ublituximab Market Overview

• Ublituximab market size has reached to $1.25 billion in 2025 • Expected to grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.3% • Growth Driver: Rising Incidence Of Autoimmune Disorders Fueling The Market Growth Due To Increasing Treatment Demand • Market Trend: Advancements In Next-Generation Monoclonal Antibodies For Enhanced Efficacy And Patient Convenience • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ublituximab Market?

Ublituximab is a monoclonal antibody designed to target the CD20 protein found on the surface of B-cells, helping to reduce abnormal or overactive B-cell activity. It works by binding to these cells and promoting their destruction through immune system mechanisms such as antibody-dependent cellular cytotoxicity. This is primarily developed for the treatment of certain blood cancers, that helps modulate immune responses and manage disease progression effectively. The main formulation types of ublituximab are intravenous (IV) and pre-filled syringes. Intravenous administration delivers medicines or fluids directly into the bloodstream through a vein, allowing for fast and controlled treatment. Ublituximab is used for indications such as chronic lymphocytic leukemia, multiple sclerosis, and non-Hodgkin lymphoma. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is utilized by end-users such as hospitals, specialty clinics, and research institutes.

What Is The Ublituximab Market Growth Forecast?

The ublituximab market size is expected to see rapid growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing development of next-generation antibodies, rising focus on treatment durability and safety, expansion into autoimmune indications, growing investments in biologics manufacturing innovation, increasing adoption of precision immunotherapy. Major trends in the forecast period include increasing adoption of cd20-targeted monoclonal antibodies, rising focus on b-cell depletion therapies, growing use of immune-modulating treatments, expansion of combination antibody regimens, enhanced optimization of antibody engineering.

Global Ublituximab Market Segmentation

1) By Formulation Type: Intravenous, Pre-Filled Syringes 2) By Indication: Chronic Lymphocytic Leukemia, Multiple Sclerosis, Non-Hodgkin Lymphoma 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Specialty Clinics, Research Institutes Subsegments: 1) By Intravenous: Single Dose Vials, Multi Dose Vials, Lyophilized Powder, Liquid Solution 2) By Pre Filled Syringes: Standard Pre Filled Syringes, Safety Engineered Pre Filled Syringes, Disposable Pre Filled Syringes, Reusable Pre Filled Syringes

What Is The Driver Of The Ublituximab Market?

The rising incidence of autoimmune disorders is expected to propel the growth of the ublituximab market going forward. Autoimmune disorders are conditions where the immune system mistakenly attacks healthy cells or where blood cell production and function are impaired, respectively. The increasing prevalence of these disorders is primarily driven by improved diagnostic capabilities and awareness, as healthcare systems are now better equipped to identify previously undiagnosed cases through advanced testing methods and expanded screening programs. Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, helps manage autoimmune disorders by selectively depleting pathogenic B cells, thereby reducing aberrant immune activity and malignant cell proliferation. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the rising incidence of autoimmune disorders is driving the growth of the ublituximab industry.

Key Players In The Global Ublituximab Market

Major companies operating in the ublituximab market are Samsung Biologics Co. Ltd., TG Therapeutics Inc.

Global Ublituximab Market Trends and Insights

Major companies operating in the ublituximab market are focusing on developing innovative products such as next-generation monoclonal antibodies to improve efficacy, reduce side effects, and enhance patient convenience. Next-generation monoclonal antibodies are engineered antibodies with improved targeting, potency, or safety profiles, helping enhance treatment effectiveness, minimize side effects, and offer more convenient dosing. For instance, in January 2023, TG Therapeutics Inc., a US-based biopharmaceutical company, launched BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, offering a one-hour infusion option and an extensive patient support program to improve accessibility and treatment adherence. The drug is a glycoengineered anti-CD20 monoclonal antibody designed to efficiently deplete B-cells, reducing relapse rates and disease activity in patients with RMS, while also minimizing potential side effects and providing a more convenient dosing schedule compared to traditional therapies. Its mechanism of action involves binding to a specific epitope on CD20-expressing B-cells, resulting to their targeted depletion through antibody-dependent cellular cytotoxicity (ADCC) and apoptosis, which helps modulate the autoimmune response underlying multiple sclerosis.

What Are Latest Mergers And Acquisitions In The Ublituximab Market?

In August 2023, TG Therapeutics Inc., a US-based biopharmaceutical company that provides ublituximab, partnered with Neuraxpharm Holdco S.a.r.l. to commercialize BRIUMVI outside the US. With this partnership, TG Therapeutics and Neuraxpharm aim to bring BRIUMVI to patients outside the US, leveraging Neuraxpharm’s extensive European neurology expertise and established presence in over 20 countries to ensure a rapid and effective launch, while TG benefits from upfront payments, milestone-based earnings, tiered royalties on sales, and the strategic flexibility to regain commercial rights in the event of a change in control. Neuraxpharm Holdco S.a.r.l. is a Germany-based pharmaceutical company that specializes in providing treatments for central nervous system (CNS) disorders.

Regional Insights

North America was the largest region in the ublituximab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ublituximab Market?

The ublituximab market consists of sales of azer-cel and tg-1701. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ublituximab Market Report 2026?

The ublituximab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ublituximab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.